BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36611989)

  • 1. Meta-Analysis of MS-Based Proteomics Studies Indicates Interferon Regulatory Factor 4 and Nucleobindin1 as Potential Prognostic and Drug Resistance Biomarkers in Diffuse Large B Cell Lymphoma.
    Ejtehadifar M; Zahedi S; Gameiro P; Cabeçadas J; da Silva MG; Beck HC; Carvalho AS; Matthiesen R
    Cells; 2023 Jan; 12(1):. PubMed ID: 36611989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary diffuse large B-cell lymphoma of the oral cavity: germinal center classification.
    Bhattacharyya I; Chehal HK; Cohen DM; Al-Quran SZ
    Head Neck Pathol; 2010 Sep; 4(3):181-91. PubMed ID: 20533006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic sub-grouping of diffuse large B-cell lymphomas into germinal centre and post germinal centre groups by immunohistochemistry after 6 cycles of chemotherapy.
    Hassan U; Mushtaq S; Mamoon N; Asghar AH; Ishtiaq S
    Asian Pac J Cancer Prev; 2012; 13(4):1341-7. PubMed ID: 22799329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods.
    Gao HX; Li SJ; Niu J; Ma ZP; Nuerlan A; Xue J; Wang MB; Cui WL; Abulajiang G; Sang W; Zhang W; Li XX
    Pathol Res Pract; 2020 Feb; 216(2):152799. PubMed ID: 31932115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p63 protein expression in high risk diffuse large B-cell lymphoma.
    Hallack Neto AE; Siqueira SA; Dulley FL; Ruiz MA; Chamone DA; Pereira J
    J Clin Pathol; 2009 Jan; 62(1):77-9. PubMed ID: 19103865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma.
    Suzuki M; Muroi A; Nojima M; Numata A; Takasaki H; Sakai R; Yokose T; Miyagi Y; Koshikawa N
    Proteomics Clin Appl; 2020 Jan; 14(1):e1900091. PubMed ID: 31721454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
    van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
    PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics.
    Anderson JJ; Fordham S; Overman L; Dignum H; Wood K; Proctor SJ; Crosier S; Angus B; Culpin RE; Mainou-Fowler T
    Int J Oncol; 2009 Nov; 35(5):961-71. PubMed ID: 19787248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma.
    Chang CC; McClintock S; Cleveland RP; Trzpuc T; Vesole DH; Logan B; Kajdacsy-Balla A; Perkins SL
    Am J Surg Pathol; 2004 Apr; 28(4):464-70. PubMed ID: 15087665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
    Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
    Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.
    Lou N; Wang G; Wang Y; Xu M; Zhou Y; Tan Q; Zhong Q; Zhang L; Zhang X; Liu S; Luo R; Wang S; Tang L; Yao J; Zhang Z; Shi Y; Yu X; Han X
    Mol Cell Proteomics; 2023 Sep; 22(9):100625. PubMed ID: 37500057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of microRNA-223 and its clinicopathologic correlation in diffuse large B-cell lymphoma].
    Yao XX; Wang JF; Wang YH; Gao N
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):366-70. PubMed ID: 22932402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum metabolomic profiling based on GC/MS helped to discriminate Diffuse Large B-cell Lymphoma patients with different prognosis.
    Mi M; Liu Z; Zheng X; Wen Q; Zhu F; Li J; Mungur ID; Zhang L
    Leuk Res; 2021 Dec; 111():106693. PubMed ID: 34455197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diffuse large B-cell lymphoma.
    Li S; Young KH; Medeiros LJ
    Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin.
    Saad AG; Grada Z; Bishop B; Abulsayen H; Hassan M; Firpo-Betancourt A; Teruya-Feldstein J; Fraig M; El Jamal SM
    Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):644-648. PubMed ID: 30179888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the molecular subtypes of diffuse large B-cell lymphomas using immunohistochemistry: a case series from the Inselspital, Bern, and a critical appraisal of this determination in Switzerland.
    Reber R; Banz Y; Garamvölgyi E; Perren A; Novak U
    Swiss Med Wkly; 2013; 143():w13748. PubMed ID: 23740154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis.
    Bodoor K; Matalka I; Hayajneh R; Haddad Y; Gharaibeh W
    Asian Pac J Cancer Prev; 2012; 13(7):3037-46. PubMed ID: 22994707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.
    Haarer CF; Roberts RA; Frutiger YM; Grogan TM; Rimsza LM
    Arch Pathol Lab Med; 2006 Dec; 130(12):1819-24. PubMed ID: 17149956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic Profiling of Diffuse Large B-Cell Lymphomas.
    Kwiecińska A; Porwit A; Souchelnytskyi N; Kaufeldt A; Larsson C; Bajalica-Lagercrantz S; Souchelnytskyi S
    Pathobiology; 2018; 85(4):211-219. PubMed ID: 29617697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.